Previous reports on the renoprotective effect of SGLT2 inhibitors have mainly analyzed the combined renal endpoints, including end-stage renal failure, creatinine doubling and death from renal disease, or a decrease in urinary albumin. Here, SLC5A2 is linked to stage 5 chronic kidney disease.